Ellie Leick

Articles

Early Data Support Neoadjuvant Hypofractionated Radiotherapy in Soft Tissue Sarcoma

November 9th 2019

Joshua M. Lawrenz, MD, discusses the use of hypofractionated radiotherapy versus conventional radiotherapy in soft tissue sarcoma.

Research Abounds in Targeting Rare Mutations in Lung Cancer

November 8th 2019

Michael D. Offin, MD, discusses ongoing research focusing on some of the less-common targetable mutations in non–small cell lung cancer.

Novel Strategies Progress Through mCRC Pipeline

November 6th 2019

Ryan B. Corcoran, MD, PhD, discusses emerging therapeutics for patients with relapsed/refractory colorectal cancer.

First-Ever Global Prospective Trial in Orthopedic Oncology Completes Accrual

November 5th 2019

Michelle Ghert, MD, FRCSC, discusses the PARITY and SAFETY trials and the future of research in orthopedic oncology.

Ongoing Research Explores Novel Approaches in Soft Tissue Sarcoma

November 2nd 2019

Albert J. Aboulafia, MD, discusses advances in tenosynovial giant cell tumor and the early research and challenges in soft tissue sarcoma treatment.

Rituximab and Trastuzumab Biosimilars Shown to Have Economic Advantage Over Originators

November 1st 2019

Jacopo Giuliani, MD, discusses the analysis of the economic impact of biosimilars in breast cancer and follicular lymphoma.

Larger Surgical Margins Not Needed for Dermatofibrosarcoma Protuberans

October 29th 2019

Ibrahim S. Alshaygy, MD, MSC, discusses surgical developments in dermatofibrosarcoma protuberans and tenosynovial giant cell tumor.

Addressing the Needs of Molecular Subgroups in CRC

October 28th 2019

Benjamin Weinberg, MD, discusses the treatment options available for the various subpopulations in metastatic colorectal cancer.

Ongoing Research in Pancreatic Cancer Focusing on Molecular Targets

October 25th 2019

Eileen M. O’Reilly, MD, discusses emerging strategies in pancreatic cancer.

CLL Treatment Moves Toward Combo Approaches and CAR T-Cell Therapy

October 24th 2019

William G. Wierda, MD, PhD, discusses the evolving treatment paradigm in chronic lymphocytic leukemia and ongoing trials looking at novel approaches.

Intriguing Research Brings Hope to Orthopedic Oncology

October 22nd 2019

R. Lor Randall, MD, FACS, discusses ongoing studies and treatment options in the orthopedic oncology landscape.

Measuring MRD Imperative to Guide ALL Treatment Decisions

October 16th 2019

Noelle Frey, MD, MS, highlights various therapies available to patients with acute lymphocytic leukemia and the importance of measuring minimal residual disease.

Novel Agents, Combo Regimens Poised to Dominate AML Treatment

October 15th 2019

Alexander Edward Perl, MD, MS, discusses advancements in acute myeloid leukemia treatment and future approaches in the field.

Myeloma Regimens Require Coping Mechanisms for Toxicity

October 14th 2019

Adam J. Waxman, MD, MS, discusses new and upcoming multiple myeloma treatments and how to optimally manage toxicities from these regimens.

Molecular Testing for NSCLC Rapidly Evolves to Include More Markers

October 11th 2019

Kristen Champion, PhD, FACMG, discusses various molecular testing methods being used in non–small cell lung cancer.

Emerging Modalities Abound in Stage III NSCLC Treatment

October 11th 2019

William T. Sause, MD, discusses various modalities of stage III non–small cell lung cancer treatment and how to effectively select patients for the varying regimens.

Open-Minded Research for Therapeutic Options Needed in TGCT

October 10th 2019

William Eward, MD, DVM, discusses the use of pexidartinib and other options to treat patients with tenosynovial giant cell tumor, as well as future recommendations for the field, such as using comparative oncology when researching drugs.

Personalized, Chemo-Free Regimens Emerging in Follicular Lymphoma

October 9th 2019

Kieron Dunleavy, MD, discusses emerging treatment options and when to use the watch-and-wait approach in follicular lymphoma.

Amid Explosion of Targeted Agents, FCR Retains a Role in CLL Paradigm

October 7th 2019

Mitchell R. Smith, MD, PhD, discusses the use of chemotherapy versus targeted therapy in patients with newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.

Technology Advances Aid Treatment Decisions for Community Oncologists

October 3rd 2019

Molecular testing has become an imperative step in the treatment decision-making process for oncologists, and new technologies and assays are emerging to further help identify tumor abnormalities and at the right time.